Granted Patent
B2
US 12,397,016 · App. 18/406,942 · Granted Aug 26, 2025
Sulfated oligosaccharides having anti-inflammatory activity
Inventors:
Katelyn Arnold (Durham, NC); Ding Xu (East Amherst, NY); Yongmei Xu (Durham, NC); Rafal Pawlinski (Chapel Hill, NC); Jian Liu (Chapel Hill, NC)
Assignees:
The University of North Carolina at Chapel Hill; THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK
View Patent ↗
Loading inventors, assignments & file history…
Abstract
Provided herein are small molecule compounds, including non-anticoagulant heparan sulfate oligosaccharide molecules, having anti-inflammatory properties and capable of interacting with high mobility group box 1 (HMGB1) proteins in a manner sufficient to affect an interaction between the HMGB1 protein and a receptor for advanced glycation end products (RAGE). Also provided herein are methods of treating Paracetamol (APAP) overdose in subjects.
Claims (10)
1. A non-anticoagulant heparan sulfate oligosaccharide molecule having an anti-inflammatory property, wherein the oligosaccharide molecule comprises one of the following structures:
wherein R 3 is H or a detectable tag.
2. The oligosaccharide molecule of claim 1 , wherein the oligosaccharide molecule is provided in a composition further comprising a compound comprising a disaccharide structure unit as shown:
wherein R=−H or −SO 3 H.
3. The oligosaccharide molecule of claim 2 , wherein the compound comprising a disaccharide structure unit is selected from the group consisting of non-anticoagulant heparin, non-anticoagulant low-molecular weight heparin, and O-desulfated heparin (ODSH).
4. The oligosaccharide molecule of claim 1 , wherein the oligosaccharide molecule protects against liver injury in vivo.
5. The oligosaccharide molecule of claim 1 , wherein the oligosaccharide molecule decreases neutrophil infiltration in vivo.
6. The oligosaccharide molecule claim 1 , wherein the oligosaccharide molecule decreases inflammation in vivo.
7. The oligosaccharide molecule of claim 1 , wherein R 3 in each structure is a detectable tag.
8. The oligosaccharide molecule of claim 1 , wherein the detectable tag in each structure is p-nitrophenyl.
Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Jul 30, 2025
From: XU, DING
To: THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK
Reel/Frame 071878/0202 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Jul 30, 2025
From: ARNOLD, KATELYN; XU, YONGMEI; PAWLINSKI, RAFAL; LIU, JIAN
To: THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL
Reel/Frame 071878/0565 →
Continuity (3)
Division
16761159
Provisional Application
62581443
· Nov 3, 2017
References Cited (400)
US 4554101A
· Hopp
· 1985
[cited by applicant]
US 4865870A
· Hu et al.
· 1989
[cited by applicant]
US 5527785A
· Bevilacqua
· 1996
[cited by examiner]
US 5543403A
· Petitou et al.
· 1996
[cited by applicant]
US 5817487A
· Kobayashi et al.
· 1998
[cited by applicant]
US 5834282A
· Habuchi et al.
· 1998
[cited by applicant]
US 5935824A
· Sgariato
· 1999
[cited by applicant]
US 6255088B1
· Wong et al.
· 2001
[cited by applicant]
US 6608044B1
· Aderka et al.
· 2003
[cited by applicant]
US 6861254B1
· Rosenberg et al.
· 2005
[cited by applicant]
US 6977248B1
· Shukla et al.
· 2005
[cited by applicant]
US 7101859B2
· Yedgar et al.
· 2006
[cited by applicant]
US 7531338B2
· Liu
· 2009
[cited by applicant]
US 8771995B2
· Liu et al.
· 2014
[cited by applicant]
US 9951149B2
· Liu et al.
· 2018
[cited by applicant]
US 20040259142A1
· Chai et al.
· 2004
[cited by applicant]
US 20050101532A1
· Yang et al.
· 2005
[cited by applicant]
US 20050191288A1
· Bennett et al.
· 2005
[cited by applicant]
US 20050282775A1
· Kennedy
· 2005
[cited by examiner]
US 20060229276A1
· Hook et al.
· 2006
[cited by applicant]
US 20090035787A1
· Liu
· 2009
[cited by applicant]
US 20090197308A1
· Liu et al.
· 2009
[cited by applicant]
US 20100305022A1
· Shriver
· 2010
[cited by applicant]
US 20110054236A1
· Yang et al.
· 2011
[cited by applicant]
US 20120064044A1
· Egan
· 2012
[cited by applicant]
US 20120322760A1
· Fier et al.
· 2012
[cited by applicant]
US 20240309035A1
· Liu et al.
· 2024
[cited by applicant]
AU 2003247808A1
· 2004
[cited by applicant]
CN 103402526A
· 2013
[cited by applicant]
CN 111601603A
· 2020
[cited by applicant]
CN 112437667A
· 2021
[cited by applicant]
CN 105452479B
· 2021
[cited by applicant]
CN 114980904A
· 2022
[cited by applicant]
EP 0394971
· 1990
[cited by applicant]
EP 0565863A
· 1993
[cited by applicant]
EP 1885865A2
· 2008
[cited by applicant]
EP 3011043A2
· 2016
[cited by applicant]
ES 2910476T3
· 2022
[cited by applicant]
ES 2924830T3
· 2022
[cited by applicant]
JP 2002534375A
· 2002
[cited by applicant]
JP 2005508827A
· 2005
[cited by applicant]
JP 2011168591A
· 2011
[cited by applicant]
JP 2014501730A
· 2014
[cited by applicant]
JP 2016523535A
· 2016
[cited by applicant]
JP 6670235
· 2020
[cited by applicant]
JP 2021502470A
· 2021
[cited by applicant]
JP 2021528421A
· 2021
[cited by applicant]
JP 2023501568A
· 2023
[cited by applicant]
JP 2023166387A
· 2023
[cited by applicant]
JP 2024056723A
· 2024
[cited by applicant]
JP 7495061B
· 2024
[cited by applicant]
JP 7538724B2
· 2024
[cited by applicant]
WO WO8904328
· 1989
[cited by applicant]
WO WO9305167A1
· 1993
[cited by applicant]
WO WO9614425
· 1996
[cited by applicant]
WO WO0151003A2
· 2001
[cited by applicant]
WO WO2003018598
· 2003
[cited by applicant]
WO WO2004005475A2
· 2004
[cited by applicant]
WO WO2004009642
· 2004
[cited by applicant]
WO WO2004017910A2
· 2004
[cited by applicant]
WO WO2004050673A2
· 2004
[cited by applicant]
WO WO2005118609
· 2005
[cited by applicant]
WO WO2006124801
· 2006
[cited by applicant]
WO WO2009014715A2
· 2009
[cited by applicant]
WO WO2009079693A1
· 2009
[cited by applicant]
WO WO2012088416A2
· 2012
[cited by applicant]
WO WO2012116048A1
· 2012
[cited by applicant]
WO WO2014204929A2
· 2014
[cited by applicant]
WO WO2018165656A1
· 2018
[cited by applicant]
WO WO2019010216A1
· 2019
[cited by applicant]
WO WO2019090203A1
· 2019
[cited by applicant]
WO WO2019246264
· 2019
[cited by applicant]
WO WO2021097345A1
· 2021
[cited by applicant]
Sommers, Journal of Pharmaceutical and Biomedical Analysis 140 (2017) 113-121. (Year: 2017).
[cited by examiner]
Nelson, Blood, vol. 82, No. 11 Dec. 1, 1993: pp. 3253-3258. (Year: 1993).
[cited by examiner]
Advisory Action corresponding to U.S. Appl. No. 13/996,930 dated Dec. 9, 2016, 6 Pages.
[cited by applicant]
Aikawa, J.I., et al., “Molecular Cloning and Expression of a Third Member of the Heparan Sulfate/Heparin GlcNAc N-Deacetylase/N-Sulfotransferase Family,” The Journal of Biological Chemistry, vol. 274, No. 5, 1999, pp. 2…
[cited by applicant]
Aikawa, J.I., et al., “Multiple Isozymes of Heparan Sulfate/Heparin GlcNAc N-Deacetylase/GlcN N-Sulfotransferase,” The Journal of Biological Chemistry, vol. 276, No. 8, pp. 5876-5882 (Feb. 23, 2001).
[cited by applicant]
Antoine, D.J., et al., “Mechanistic Biomarkers Provide Early And Sensitive Detection Of Acetaminophen-Induced Acute Liver Injury At First Presentation To Hospital,” Hepatology vol. 58, pp. 777-787 (2013).
[cited by applicant]
Applicant-Initiated Interview Summary corresponding to U.S. Appl. No. 13/996,930 dated Jan. 23, 2017.
[cited by applicant]
Arepally, G, M., et al., “Clinical Practice. Heparin-Induced Thrombocytopenia,” N. Eng. J. Med., vol. 355, pp. No. 8, pp. 809-817, Aug. 24, 2006.
[cited by applicant]
Arnold, K., et al., “Design Of Anti-Inflammatory Heparan Sulfate To Protect Against Acetaminophen-Induced Acute Liver Failure,” Sci. Transl. Med., vol. 12, No. 535, pp. 1-26, Article ID eaav8075 (Mar. 18, 2020).
[cited by applicant]
Arnold, K., et al., “Potential Use of Anti-Inflammatory Synthetic Heparan Sulfate to Attenuate Liver Damage,” Biomedicines, vol. 8, 0503, 1-15 pages, 2020.
[cited by applicant]
Arnold, K., et al., “Synthetic anticoagulant heparan sulfate attenuates liver ischemia reperfusion injury,” Sci. Reports, vol. 10, Article No. 17187 (10 pages) (2020).
[cited by applicant]
Arungundram, S., et al., “Modular Synthesis of Heparan Sulfate Oligosaccharides for Structure-Activity Relationship Studies,” J. Am. Chem. Soc., vol. 131, pp. 17394-17405, Dec. 2, 2009.
[cited by applicant]
Ashikari-Hada, S., et al., “Characterization of growth factor-binding structures in heparin/heparan sulfate using an octasaccharide library,” J. Biol. Chem., vol. 279, No. 13, pp. 12346-12354, Mar. 26, 2004.
[cited by applicant]
Axelsson, J., et al., “Inactivation Of Heparan Sulfate 2-O-Sulfotransferase Accentuates Neutrolphil Infiltration During Acute Inflammation In Mice,” Blood, vol. 120, pp. 1742-1751 (2012).
[cited by applicant]
Bailey, G.P., et al., “Delays During The Administration Of Acetylcysteine For The Treatment Of Paraacetamol Overdose,” Br. J. Clin. Pharmacol. vol. 62, pp.
[cited by applicant]
Baleux, F., et al., “A Synthetic CD4-Heparan Sulfate Glycoconjugate Inhibits CCR5 And CXCR4 HIV-1 Attachment and Entry,” Nat. Chem. Biol., vol. 5, No. 10, pp. 743-748, Oct. 2009.
[cited by applicant]
Bame, K. J., et al., “Undersulfated Heparan Sulfate In A Chinese Hamster Ovary Cell Mutant Defective In Heparan Sulfate N-Sulfotransferase,” J Biol. Chem, vol. 264, No. 14, pp. 8059-8065, May 15, 1989.
[cited by applicant]
Beeson, J.G., et al., “Inhibition of Binding of Malaria-Infected Erythrocytes by a Tetradecasaccharide Fraction from Chondroitin Sulfate A,” Infection and Immunity, vol. 66 No. 7 pp. 3397-3402 (Year: 1998).
[cited by applicant]
Belot, F., et al., “Syntheses Of Chondroitin 4- And 6-Sulfate Pentasaccharide Derivatives Having A Methyl Beta-D-Glucopyranosiduronic Acid At The Reducing End,” Carbohyd. Res., vol. 326, pp. 88-97. (Year: 2000).
[cited by applicant]
Bianchi, M.E., et al., “High-Mobility Group Box 1 Protein Orchestrates Responses To Tissue Damage Via Inflammation, Innate And Adaptive Immunity, And Tissue Repair,” Immunol. Rev. vol. 280, pp. 74-82 (2017).
[cited by applicant]
Bitter T., et al., “A Modified Uronic Acid Carbazole Reaction,” Anal. Biochem., vol. 4, pp. 330-334, 1962.
[cited by applicant]
Blieden, M., et al., “A Perspective On The Epidemiology Of Acetaminophen Exposure And Toxicity In The United States,” Expert Rev. Clin. Pharmacol. vol. 7, pp. 341-348 (2014).
[cited by applicant]
Bourgeaux, V., et al., “Two-Step Enzymatic Synthesis Of UDP-N-Acetylgalactosamine,” Bioorg. Med. Chem. Lett., vol. 15, pp. 5459-5462 (2005).
[cited by applicant]
Bowman, K.G., et al., “Carbohydrate Sulfotransferases: Medliators Of Extracellular Communication,” Chemistry & Biology, vol. 6, pp. R9-R22 (Jan. 1999).
[cited by applicant]
Bradbury, E.J., et al., “Chondroitinase ABC Promotes Functional Recovery After Spinal Cord Injury,” Nature, vol. 416, pp. 636-640 (2002).
[cited by applicant]
Brinkmann, V., et al., “Neutrophil Extracellular Traps Kill Bacteria,” Science, vol. 303, pp. 1532-1535, 2004.
[cited by applicant]
Broun, P., et al., “Catalytic plasticity of fatty acid modification enzymes underlying chemical diversity of plant lipids,” Science, vol. 282, pp. 1315-1317 (1998).
[cited by applicant]
Brown, J. M., et al., “A Sulfated Carbohydrate Epitope Inhibits Axon Regeneration After Injury,” Proc. Natl. Acad. Sci. USA, vol. 109, pp. 4768-4773 (2012).
[cited by applicant]
Brown, L., et al., “Cardenolide Analogues. 11. Improved Method For The Use Of Fetizon's Reagent In The Synthesis Of Cardiac Glycosides,” Drug Research, vol. 31, No. 7, pp. 1059-1064 (1981).
[cited by applicant]
Burkart, M, D., et al., “Regeneration of PAPS for the Enzymatic Synthesis of Sulfated Oligosaccharides,” J. Org. Chem., vol. 65, pp. 5565-5574 (2000).
[cited by applicant]
Cai, C., et al., “Towards The Chemoenzymatic Synthesis Of Heparan Sulfate Oligosaccharides: Oxidative Cleavage Of P-Nitrophenyl Group With Ceric Ammonium Salts,” Tetra. Lett., vol. 54, No. 33, pp. 4471-4474 (2013).
[cited by applicant]
Capila, I., et al., “Heparin—Protein Interactions,” Angew. Chem. Int. Ed., vol. 41, pp. 390-412 (2002).
[cited by applicant]
Carfi, A., et al., “Herpes Simplex Virus Glycoprotein D Bound to the Human Receptor HveA,” Molecular Cell, vol. 8, pp. 169-179 (Jul. 2001).
[cited by applicant]
Cassinelli, G., et al., “Old And New Applications Of Non-Anticoagulant Heparin,” International Journal of Cardiology, 212S1 pp. S14-S21 (2016).
[cited by applicant]
Casu, B., et al., “Heparin-Like Compounds Prepared By Chemical Modification Of Capsular Polysaccharide From
[cited by applicant]
Chan, S., et al., “Regulation Of Pfemp1-VAR2CSA Translation By A Plasmodium Translation-Enhancing Factor,” Nature Microbiology, vol. 2, Article No. 17068 (May 8, 2017).
[cited by applicant]
Chen, G, Y., et al., “Sterile Inflammation: Sensing And Reacting To Damage,” Nat. Immunol. vol. 10, pp. 826-837 (2010).
[cited by applicant]
Chen, J., et al., “Using an Enzymatic Combinatorial Approach to Identify Anticoagulant Heparan Sulfate Structures,” Chemistry and Biology, Current Biology, London, GB, vol. 14., No. 9, pp. 986-993 (Sep. 19, 2007).
[cited by applicant]
Chen, M., et al., “Determination of the Substrate Specificities of N-Acetyl-D-glucosaminyltransferase,” Biochemistry, vol. 45, pp. 12358-12365, 2006.
[cited by applicant]
Chen, R., et al., “Release And Activity Of Histone In Disease,” Cell Death and Disease, vol. 5, No. 8, e1370, Aug. 14, 2014.
[cited by applicant]
Chen., et al., Towards De Novo Synthesis of Structure-Defined Oligosaccharides with Heparan Sulfate Biosynthetic Enzymes, PhD dissertation. 1-167, (Date Created: Aug. 2008; Date Deposited: Oct. 11, 2010.).
[cited by applicant]
Chica R.A., et al., “Semi-rational Approaches to Engineering Enzyme Activity: Combining the Benefits of Directed Evolution and Rational Design,” Current Opinion in Biotechnology, vol. 16, No. 4, Aug. 2005, pp. 378-384.
[cited by applicant]
Clark, S. R., et al., “Platelet TLR4 activates neutrophil extracellular traps to ensnare bacteria in septic blood,” Nat Med., vol. 13, No. 4, pp. 463-469, 2007.
[cited by applicant]
Cole, C.L., et al., “Synthetic Heparan Sulfate Oligosaccharides Inhibit Endothelial Cell Functions Essential for Angiogenesis” Plos One, vol. 5, issue 7, pp. 1-15. (Year: 2010).
[cited by applicant]
Communication of European publication number and information on the application of Article 67(3) EPC corresponding to European Application No. 14812890.3 dated Mar. 31, 2016.
[cited by applicant]
Communication of European publication number corresponding to European Patent application No. 20887629.2 dated Jul. 20, 2022.
[cited by applicant]
Communication of the extended European search report corresponding to European Application No. 14812890.3 dated Dec. 21, 2016.
[cited by applicant]
Communication of the extended European Search report corresponding to European Patent Application No. 20887629.2 dated Oct. 27, 2023.
[cited by applicant]
Communication pursuant to Article 94(3) EPC Corresponding to European Patent Application No. 19822610.2-1109 dated Sep. 30, 2024, pp. 5.
[cited by applicant]
Communication under Rule 71(3) EPC (Intention to Grant) corresponding to European Patent Application No. 18873131.9-1109 dated Oct. 16, 2024, 7 Pages.
[cited by applicant]
Conrad, H, E., “Heparin-Binding Proteins,” J. of Medicinal Chemistry, vol. 42, No. 4, pp. 777-778 (1998).
[cited by applicant]
Copeland, R., et al., “Using a 3-O-Sulfated Heparin Octasaccharide to Inhibit the Entry of Herpes Simplex Virus Type 1,” Biochemistry, vol. 47, pp. 5774-5783 (2008).
[cited by applicant]
Corrected Notice of Allowance corresponding to U.S. Appl. No. 16/492,858 dated Sep. 20, 2022.
[cited by applicant]
Coutant, C., et al., “2-Deoxy-2-Trichloroacetamido-D-Glucopyranose Derivatives In Oligosaccharide Synthesis: From Hyaluronic Acid To Chondroitin 4-Sulfate Trisaccharides” J Chem Soc Perkin Trans 1, pp. 1573-1581 (Year: …
[cited by applicant]
Crowther, M, A., et al., “Mechanisms Responsible For The Failure Of Protamine To Inactivate Low-Molecular-Weight Heparin,” British Journal of Hematology, vol. 116, pp. 178-186 (2002).
[cited by applicant]
Darden, T., et al., “Particle Mesh Ewald: An N⋅Log(N) Method For Ewald Sums In Large Systems,” J. Chem. Phys. 1993, vol. 98, No. 12, pp. 10089-10092.
[cited by applicant]
Das, S.K., et al., “Synthesis of Conformationally Locked I-Iduronic Acid Derivatives: Direct Evidence for a Critical Role of the Skew-Boat 280 Conformer in the Activation of Antithrombin by Heparin,” Chem. Eur. J., vol.…
[cited by applicant]
Davenport, A., “Review Article: Low-Molecular-Weight Heparin As An Alternative Anticoagulant To Unfractionated Heparin For Routine Outpatient Haemodialysis Treatments,” Nephrology, vol. 14, pp. 455-461 (2009).
[cited by applicant]
De Paz, J.L., et al., “Microarrays of Synthetic Heparin Oligosaccharides,” Journal of the American Chemical Society, vol. 128, No. 9, Mar. 8, 2006, pp. 2766-2767.
[cited by applicant]
Deagostini, A.I., et al., “Human Follicular Fluid Heparan Sulfate Contains Abundant 3-O-Sulfated Chains with Anticoagulant Activity,” J. Biol. Chem., vol. 283, pp. 28115-28124, Oct. 17, 2008.
[cited by applicant]
Decision to Grant corresponding to European Patent Application No. 14812890.3 dated Apr. 14, 2022.
[cited by applicant]
Decision to Grant corresponding to Japanese Patent Application No. 2016521505 dated Feb. 3, 2020.
[cited by applicant]
Decision to Grant corresponding to Japanese Patent Application No. 2019549419 dated Jul. 11, 2023.
[cited by applicant]
Devos D., et al., “Practical Limits of Function Prediction,” Proteins: Structure, Function, and Genetics, vol. 41, No. 1, Oct. 1, 2000, pp. 98-107.
[cited by applicant]
Dooley, T.P., “Cloning Of The Human Phenol Sulfotransferase Gene Family: Three Genes Implicated In The Metabolism Of Catecholamines, Thyroid Hormones And Drugs,” Chemico-Biological Interactions, vol. 109, pp. 29-41 (199…
[cited by applicant]
Dou, W., et al., “Role of Deacetylase Activity of N-Deacetylase/N-Sulfotransferase 1 in Forming N-Sulfated Domain in Heparan Sulfate”, The Journal of Biological Chemistry, vol. 290, No. 33, pp. 20427-20437 (Aug. 14. 201…
[cited by applicant]
Edens, R,E., et al., “Gradient Polyacrylamide Gel Electrophoresis for Determination of Molecular Weights of Heparin Preparations and Low-Molecular-Weight Heparin Derivatives,” J. Pharm. Sci., vol. 81, No. 8, pp. 823-827…
[cited by applicant]
Eller, S., et al., “Automated Solid-Phase Synthesis of Chondroitin Sulfate Glycosaminoglycans,” Angew. Chem. Int. Ed., vol. 52, pp. 5858-5861 (2013).
[cited by applicant]
Esko, J,D.,et al., “Molecular diversity of heparan sulfate,” J. Clin. Invest., vol. 108, pp. 169-173 (2001).
[cited by applicant]
European Search Report corresponding to European Patent Application No. 18764628.6 dated Dec. 2, 2020.
[cited by applicant]
European Search Report corresponding to European Patent Application No. 18873131.9 dated Jul. 12, 2021.
[cited by applicant]
Extended European Search Report Corresponding to European Patent Application No. 19822610.2 dated Mar. 29, 2022.
[cited by applicant]
Extended European Search Report Corresponding to European Patent Application No. 06770377.7 dated Nov. 22, 2010.
[cited by applicant]
Falany, C.N., “Introduction: Changing view of sulfation and the cytosolic Sulfotransferases,” vol. 11, The FASEB Journal, pp. 1-2 (Jan. 1997).
[cited by applicant]
Feltracco, P., et al., “Perioperative thrombotic complications in liver transplantation.” World J. Gastroenterol., vol. 21, pp. 8004-8013 (2015).
[cited by applicant]
Feng. S., et al., “Characteristics Associated with Liver Graft Failure: The Concept of a Donor Risk Index.” Am. J. Transplant., vol. 6, pp. 783-790 (2006).
[cited by applicant]
Feyerabend, T.B., et al., “Heparan sulfate C5-epimerase is essential for heparin biosynthesis in mast cells,” Nat. Chem. Biol., vol. 2, No. 4, pp. 195-196 (Apr. 2006).
[cited by applicant]
Fiser, A., et al., “Modeller: Generation and Refinement of Homology-Based Protein Structure Models,” Methods Enzymol, vol. 374, pp. 461-491, 2003.
[cited by applicant]
Frank, R.D., et al., “A non-anticoagulant synthetic pentasaccharide reduces inflammation in a murine model of kidney ischemia-reperfusion injury,” Thromb Haemost, vol. 96, pp. 802-806. (Dec. 2006).
[cited by applicant]
Freeman, C,G., et al., “The accumulation of circulating histones on heparan sulphate in the capillary glycocalyx of the lungs.” Biomater., vol. 34, pp. 5670-5676 (2013).
[cited by applicant]
Fried, M., et al., “Designing a VAR2CSA-based vaccine to prevent placental malaria.” Vaccine, vol. 33, pp. 7483-7488 (2015).
[cited by applicant]
Fukuta, M., et al., “Molecular cloning and expression of human chondroitin 6-sulfotransferase,” Biochimica et Biophysica Acta, vol. 1399, pp. 57-61 (1998).
[cited by applicant]
Fuster, J. J., et al., “The sweet and sour of cancer: glycans as novel therapeutic targets,” Nat. Rev. Cancer, vol. 5, No. 7, pp. 1-27 (Jul. 2005).
[cited by applicant]
Gama, C.I., et al., “Sulfation patterns of glycosaminoglycans encode molecular recognition and activity,” Nat Chem. Biol., vol. 2, No. 9, pp. 467-473 (Sep. 2006).
[cited by applicant]
Ganey, P,E., et al. “Role of the Coagulation System in Acetaminophen-Induced Hepatotoxicity in Mice.” Hepatology, vol. 46(4), pp. 1177-1186 (2007).
[cited by applicant]
Goddard-Borger, E, D., et al., “An Efficient, Inexpensive and Shelf-Stable Diazotransfer Reagent: Imidazole-1-sulfonyl Azide Hydrochloride.” Org. Lett., vol. 9, pp. 3797-3800 (2007).
[cited by applicant]
Guerrini, M., et al., “An unusual antithrombin-binding heparin octasaccharide with an additional 3-O-sulfated glucosamine in the active pentasaccharide sequence,” Biochem. J., vol. 449, pp. 343-351, 2013.
[cited by applicant]
Guerrini, M., et al., “Antithrombin-binding oligosaccharides: structural diversities in a unique function?,” Glycoconj. J., vol. 31, 409, pp. 9, Aug. 2014.
[cited by applicant]
Guerrini, M., et al., “Oversulfated chondroitin sulfate is a contaminant in heparin associated with adverse clinical events,” Nat. Biotechnol., vol. 26, No. 6, pp. 669-675 (Jun. 2008).
[cited by applicant]
Habuchi, H., et al., “Molecular Characterization and Expression of Heparan-sulfate 6-Sulfotransferase—Complete cDNA Cloning in Human and Partial Cloning in Chinese Hamster Ovary Cells,” The Journal of Biological Chemist…
[cited by applicant]
Habuchi, O., et al., “Purification of Chondroitin 6-Sulfotransferase Secreted from Cultured Chick Embryo Chondrocytes,” The Journal of Biological Chemistry, vol. 268(29), pp. 21968-21974 (1993).
[cited by applicant]
Hagiwara, S., et al., “Danaparoid sodium inhibits systemic inflammation and prevents endotoxin-induced acute lung Injury in rats,” Critical Care, vol. 12, No. 2, report No. R43, Apr. 2, 2008.
[cited by applicant]
Orgaran, Product Monograph—HIT for danaparoid sodium, pp. 41, Feb. 9, 2018. (Year: 2018).
[cited by applicant]
Hajmohammadi, S., “Normal levels of anticoagulant heparan sulfate are not essential for normal hemostasis,” The Journal of Clinical Investigation, vol. 111, pp. 989-999, No. 7, Apr. 2003.
[cited by applicant]
Hansen, S. U., et al., “First gram-scale synthesis of a heparin-related dodecasaccharide,” Org. Lett., vol. 15, No. 1, pp. 88-91, Jan. 4, 2013.
[cited by applicant]
Hansen, S.U., “Tetrasaccharide iteration synthesis of a heparin-like dodecasaccharide and radiolabelling for in vivo tissue distribution studies,” Nature Communications, vol. 4, Article No. 2016, pp. 1-9, May 16, 2013.
[cited by applicant]
Harada, N., et al., “Danapariod sodium reduces ischemia/reperfusion-induced liver injury in rats by attenuating inflammatory responses” Thromb Haemost, 2007; 97; pp. 81-87.
[cited by applicant]
Harada, N., et al., “Dalteparin, a low molecular weight heparin, attenuates inflammatory responses and reduces ischemia-reperfusion-induced liver injury in rats.” Crit. Care Med., vol. 34, Article No. 8, (2006).
[cited by applicant]
Harder, S., “Renal profiles of anticoagulants,” J. Clin. Pharmacol., vol. 52, No. 7, pp. 964-975, Jul. 2012.
[cited by applicant]
Harris, E. N., “The human hyaluronan receptor for endocytosis (HARE/Stabilin-2) is a systemic clearance receptor for heparin,” J. Biol. Chem., vol. 283, No. 25, pp. 17341-17350, Jun. 20, 2008.
[cited by applicant]
Harris, E.N., et al., “Endocytic Function, Glycosaminoglycan Specificity, and Antibody Sensitivity of the Recombinant Human 190-kDa Hyaluronan Receptor for Endocytosis (HARE),” J. Biol. Chem., vol. 279, No. 35, pp. 3620…
[cited by applicant]
Heard, K.J., “Acetylcystein for acetaminophen poisoning,” N. Eng. J. Med. vol. 359, pp. 285-292 (2008).
[cited by applicant]
Hirsch, J., et al., “Beyond Unfractionated Heparin and Warfarin Current and Future Advances,” Circulation, vol. 116, pp. 552-560 (2007).
[cited by applicant]
Hirsch, J., et al., “Heparin and Low-Molecular-Weight Heparin The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy,” Chest, vol. 126, pp. 188S-203S (2004).
[cited by applicant]
Hsieh, P-H., “Uncovering the Relationship between Sulphation Patterns and Conformation of Iduronic Acid in Heparan Sulphate,” J. Sci Rep, vol. 6, Article No. 29602, pp. 1-8, 2016.
[cited by applicant]
Hsieh, P-H., et al., “Chemoenzymatic synthesis and structural characterization of 2-O-sulfated glucuronic acid containing heparan sulfate hexasaccharides.” Glycobiology vol. 24, pp. 681-692 (2014).
[cited by applicant]
Hu, Y-P., et al.,“Synthesis of 3-O-sulfonated heparan sulfate octasaccharides that inhibit the herpes simplex virus type 1 host-cell interaction,” Nat Chem, vol. 3, pp. 557-563, Jul. 2011.
[cited by applicant]
Huang, C. C., et al., “Enhancing UCSF Chimera through web services,” Nucleic Acids Res., vol. 42, pp. W478- W484, May 26, 2014.
[cited by applicant]
Huebener, P., el al., “The HMGB1/RAGE axis triggers neutrophil-mediated injury amplification following necrosis.” J. Clin. Invest., vol. 125, pp. 539-550 (2015).
[cited by applicant]
Humphrey, W., “VMD: Visual Molecular Dynamics,” J. Mol. Graph., vol. 14, pp. 33-38, 1996.
[cited by applicant]
Iba et al., “Danaparoid sodium attenuates the increase in inflammatory cytokines and preserves organ function in endotoxemic rats,” Critical Care, vol. 12, Article No. R86 (7 pages) (2008).
[cited by applicant]
Iba, T., et al., “Advance in the management of sepsis-induced coagulopathy and disseminated intravascular coagulation.” J. Clin. Med., vol. 8, Article No. 728 (16 pages) (2019).
[cited by applicant]
Intention to Grant corresponding to European Patent Application No. 11849994.6 dated Apr. 7, 2021.
[cited by applicant]
Intention to Grant corresponding to European Patent Application No. 11849994.6 dated Sep. 1, 2021.
[cited by applicant]
Intention to Grant corresponding to European Patent Application No. 14812890.3 dated Oct. 27, 2021.
[cited by applicant]
Intention to Grant corresponding to European Patent Application No. 14812890.3 dated Mar. 16, 2022.
[cited by applicant]
International Preliminary Examination Report for corresponding PCT Application No. PCT/US2008/008945 dated Jan. 26, 2010.
[cited by applicant]
International Preliminary Report on Patentability corresponding to International Application No. PCT/US2018/040774 dated Jan. 7, 2020.
[cited by applicant]
International Preliminary Report on Patentability corresponding to International Application No. PCT/US2019/037993 dated Dec. 22, 2020.
[cited by applicant]
International Preliminary Report on Patentability Corresponding to International Patent Application No. PCT/US2020/060581 dated May 17, 2022.
[cited by applicant]
International Preliminary Report on Patentability corresponding to International Application No. PCT/US2014/042683 dated Dec. 22, 2015.
[cited by applicant]
International Preliminary Report on Patentability corresponding to International Application No. PCT/US2011/066843 dated Jun. 25, 2013.
[cited by applicant]
International Preliminary Report on Patentability Corresponding to International application No. PCT/US2018/021986 dated Sep. 10, 2019.
[cited by applicant]
International Preliminary Report on Patentability corresponding to international application No. PCT/US2018/059152 dated May 5, 2020.
[cited by applicant]
International Search Report and the Written Opinion of the International Searching Authority Corresponding to International Application No. PCT/US 2018/040774 dated Sep. 18, 2018.
[cited by applicant]
International Search Report and the Written Opinion of the International Searching Authority corresponding to international application No. PCT/US 2018/059152 dated Mar. 6, 2019.
[cited by applicant]
International Search Report and Written Opinion of the International Searching Authority Corresponding to International Patent Application No. PCT/US2020/060581 dated Feb. 11, 2021.
[cited by applicant]
International Search Report corresponding to International Application No. PCT/US2019/037993 dated Oct. 18, 2019.
[cited by applicant]
International Search Report corresponding to International Application No. PCT/US2014/042683 dated Oct. 9, 2014.
[cited by applicant]
International Search Report Corresponding to International application No. PCT/US 2018/021986 dated Aug. 1, 2018.
[cited by applicant]
Jackson, S,P., et al., “Thromboinflammation: challenges of therapeutically targeting coagulation and other host defense mechanisms.” Blood, vol. 133, pp. 906-918 (2019).
[cited by applicant]
Jaeschke, H., et al., “Complement activates Kupffer cells and neutrophils during reperfusion after hepatic ischemia.” Am. J. Physiol-Gastroint. Liver Physiol., vol. 264, pp. G801-G809 (1993).
[cited by applicant]
Jaimes, F., et al., “Unfractioned heparin for treatment of sepsis: A randomized clinical trial (The HETRASE Study).” Crit. Care Med., vol. 37, pp. 1185-1196 (2009).
[cited by applicant]
Jemth, P., et al., “Oligosaccharide library-based assessment of heparan sulfate 6-0-sulfotransferase substrate specificity,” Journal of Biological Chemistry, vol. 278, No. 27, pp. 24371-24376 (Jul. 4, 2003).
[cited by applicant]
Jin, L., et al., “The anticoagulant activation of antithrombin by heparin,” Proc. Natl. Acad. Sci., vol. 94, pp. 14683-14688, Dec. 1997.
[cited by applicant]
Kahn, S. R. et al., “Prevention of VTE in nonsurgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines,” Chest 141 (…
[cited by applicant]
Kakkar, A, K., et al., “Low Molecular Weight Heparin, Therapy With Dalteparin, and Survival in Advanced Cancer: The Fragmin Advanced Malignancy Outcome Study (Famous),” J. Clin. Oncol., vol. 22, No. 10, pp. 1944-1948 (M…
[cited by applicant]
Kakuta, Y., et al., “Heparan sulphate N-sulphotransferase activity: reaction mechanism and substrate recognition,” Biochem. Soc. Trans., vol. 31 (pt2), pp. 331-334 (2003).
[cited by applicant]
Kamimura, K., et al., “Regulation of Notch signaling by
[cited by applicant]
Kaneko, J., et al., “Coagulation and fibrinolytic profiles and appropriate use of heparin after living-donor liver transplantation.” Clin. Transplant., vol. 19, pp. 804-809 (2005).
[cited by applicant]
Kirschner, K. N., et al., “GLYCAM06: A Generalized Biomolecular Force Field. Carbohydrates,” J. Comput. Chem., vol. 29, No. 4, pp. 622-655, Mar. 2008.
[cited by applicant]
Kishimoto, T. K. et al., “Contaminated heparin associated with adverse clinical events and activation of the contact system,” N. Engl. J. Med., vol. 358, No. 23, pp. 2457-2467, Jun. 5, 2008.
[cited by applicant]
Kisselev, L., “Polypeptide release factors in prokaryotes and eukaryotes: same function, different structure,” Structure, vol. 10, pp. 8-9 (2002).
[cited by applicant]
Kobayashi, M., et al., “Purification and characterization of heparan sulfate 2-sulfotransferase from cultured Chinese hamster ovary cells,” J Biol. Chem. vol. 271, No. 13, pp. 7645-7653, Mar. 29, 1996.
[cited by applicant]
Kollman, P., A., et al., “Calculating Structures and Free Energies of Complex Molecules: Combining Molecular Mechanics and Continuum Models,” Acc. Chem. Res., vol. 33, pp. 889-897, 2000.
[cited by applicant]
Konishi, T., et al., “Hepatic ischemia/reperfusion: mechanisms of tissue injury, repair, and regeneration.” Gene Expr., vol. 17, pp. 277-287 (2017).
[cited by applicant]
Kopec, A. K., et al., “Fibrin(ogen) drives repair after acetaminophen-induced liver injury via leukocyte aMb2 integrin-dependent upregulation of Mmp12.” J. Hepatol., vol. 66, pp. 787-797 (2017).
[cited by applicant]
Kreimann, M., et al., “Binding of anti-platelet factor 4/heparin antibodies depends on the thermodynamics of conformational changes in platelet factor 4,” Blood, vol. 124, No. 15, pp. 2442-2449, Oct. 9, 2014.
[cited by applicant]
Kreuger,J., et al., “Interactions between heparan sulfate and proteins: the concept of specificity,” J. Cell Biol., vol. 174, No. 3, pp. 323-327 (Jul. 31, 2006).
[cited by applicant]
Kuberan, B., et al., “Enzymatic synthesis of antithrombin III-binding heparan sulfate pentasaccharide,” Nature Biotechnology, vol. 21, No. 11, 1343-1346 (Nov. 2003).
[cited by applicant]
Kuberan, B., et al., The Journal of Biological Chemistry, “Chemoenzymatic Synthesis of Classic and Non-classical Anticoagulant Heparan Sulfate Polysaccharides”, 2003, vol. 278, No. 52, pp. 52613-52621 (Year: 2003).
[cited by applicant]
Kubes, et al., “Sterile inflammation in the liver.” Gastroenterology, vol. 143, pp. 1158-1172 (2012).
[cited by applicant]
Langdown, J.; Belzar, K. J.; Savory, W. J., Baglin, T. P.; Huntington, J. A. J. Mo/. Biol. 2009, 386, 1278.
[cited by applicant]
Laremore, T. et al.“Ionic liquid matrix for direct UV-MALDI-TOF-MS Analysis of Dermatan Sulfate and Chondroitin Sulfate Oligosaccharides.” Anal. Chem., vol. 79, pp. 1604-1610. (Year: 2007).
[cited by applicant]
Laurent et al., “The Molecular-Weight-Dependence of the Anti-Coagulant Activity of Heparin,” Biochem. J., vol. 175, pp. 691-701 (1978).
[cited by applicant]
Ledin et al., “Heparan Sulfate Structure in Mice with Genetically Modified Heparan Sulfate Production,” J. Biol. Chem., vol. 279, No. 41, pp. 42732-42741 (2004).
[cited by applicant]
Lee, “Acetaminophen toxicity: changing perceptions on a social/medical issue.” Hepatology, vol. 46, pp. 966-970 (2007).
[cited by applicant]
Lee, M.K., and Lander, A.D., (1991) Proc. Natl. Acad. Sci. USA 88, 2768-2772.
[cited by applicant]
Li et al., “Biosynthesis of Heparin/Heparan Sulfate cDNA Cloning and Expression of D-Glucuronyl C5-Epimerase From Bovine Lung,” J. Biol. Chem., vol. 272, No. 4, pp. 28158-28163 (Oct. 31, 1997).
[cited by applicant]
Li et al., “Enzymatic Synthesis of Homogeneous Chondroitin Sulfate Oligosaccharides.” Angew. Chemie., vol. 129(39), pp. 11946-11949 (2017).
[cited by applicant]
Li et al., “Enzymatic synthesis of homogenous chondroitin sulfate e oligosaccharides,” Abstract of Glycobiol., vol. 28(12) (2018) [Abstract].
[cited by applicant]
Li J, Su W, and Liu J. “Enzymatic synthesis of homogeneous chondroitin sulfate oligosaccharides.” Angew Chem Int Ed. 2017: 56:11784-7.
[cited by applicant]
Li, J., et al., “Enzymatic Synthesis of Chondroitin Sulfate E to Attenuate Bacteria Lipopolysaccharide-induced Organ Damage,” ACS Central Science, vol. 6, No. 7, pp. 1199-1207, Jul. 1, 2020.
[cited by applicant]
Li, L., et al., “Top-down approach for the direct characterization of low molecular weight heparins using LC-FR-MS,” Anal. Chem., vol. 84, No. 20, pp. 8822-8829, Oct. 16, 2012.
[cited by applicant]
Liliensiek et al., “Receptor for advanced glycation end products (RAGE) regulates sepsis but not the adaptive immune response.” J. Clin. Invest. vol. 113, pp. 1641-1650 (2004).
[cited by applicant]
Lindahl et al., “Regulated Diversity of Heparan Sulfate,” The Journal of Biological Chemistry, vol. 273, No. 39, pp. 24979-24982 (Sep. 25, 1998).
[cited by applicant]
Lindahl, U.; Backstrom, G.; Thunberg, L.; Leder, I. G. Proc. Natl. Acad. Sci. 1980, 77, pp. 6551-6555.
[cited by applicant]
Linhardt et al., “Production and Chemical Processing of Low Molecular Weight Heparins,” Seminars in Thrombosis and Hemostasis, vol. 25, Suppl.3, pp. 5-16 (1999).
[cited by applicant]
Linhardt, R. J., et al., “Synthetic heparin,” Curr. Opin. Pharmacol, vol. 12, No. 2, pp. 217-219, Apr. 2012.
[cited by applicant]
Liu et al., “Anticoagulant heparan sulfate: structural specificity and biosynthesis,” Appl Microbiol Biotechnol., vol. 74, pp. 263-272 (2007).
[cited by applicant]
Liu et al., “Cell Surface Heparan Sulfate and Its Roles in Assisting Viral Infections,” Medicinal Research Reviews, vol. 22, No. 1, pp. 1-25 (2002).
[cited by applicant]
Liu et al., “Characterization of a Heparan Sulfate Octasaccharide that Binds to Herpes Simplex Virus Type 1 Glycoprotein D,” The Journal of Biological Chemistry, vol. 277, No. 36, pp. 33456-33467 (Sep. 6, 2002).
[cited by applicant]
Liu et al., “Expression of Heparan Sulfate D-Glucosaminyl 3-O-Sulfotransferase Isoforms Reveals Novel Substrate Specificities,” The Journal of Biological Chemistry, vol. 274, No. 8, pp. 5185-5192 (Feb. 19, 1999).
[cited by applicant]
Liu et al., “Heparan Sulfate D-Glucosaminyl 3-O-Sulfotransferase-3A Sulfates N-Unsubstituted Glucosamine Residues,” The Journal of Biological Chemistry vol. 274, No. 53, pp. 38155-38162 (Dec. 31, 1999).
[cited by applicant]
Liu et al., “Purification of Heparan Sulfate D-Glucosaminyl 3-O-Sulfotransferase,” The Journal of Biological Chemistry, vol. 271, No. 43, pp. 27072-27082 (Oct. 25, 1996).
[cited by applicant]
Liu et al., Chemoenzymatic Design of Heparan Sulfate Oligosaccharides, J Biol Chem, vol. 285, No. 44, pp. 34240-34249 (Oct. 29, 2010).
[cited by applicant]
Liu et al., “Enzymatic Placement of 6-O-Sulfo Groups in Heparan Sulfate,” Biochemistry 2011, 50, 4382-4391.
[cited by applicant]
Liu et al., “Lessons learned from the contamination of heparin,” Nat. Prod. Rep., vol. 26, pp. 313-321 (2009).
[cited by applicant]
Liu, J. et al., “Chemoenzymatic synthesis of heparan sulfate and heparin”, Royal Society of Chemistry, vol. 31, pp. 1676-1685 (Year: 2014).
[cited by applicant]
Loganathan et al., “Structural Variation in the Antithrombin III Binding Site Region and Its Occurrence in Heparin from Different Sources,” Biochemistry, vol. 29, pp. 4362-4368 (1990).
[cited by applicant]
Lopin et al., “From Polymer to Size-Defined Oligomers: An Expeditious Route for the Preparation of Chondroitin Oligosaccharides.” Angew. Chem. Int. Ed., vol. 45, pp. 2574-2578 (2006).
[cited by applicant]
Lopin-Bon et al., “Stereocontrolled preparation of biotinylated chondroitin sulfate E di-, tetra-, and hexasaccharide conjugates.” Carbohydr. Res., vol. 402, pp. 35-43 (2015).
[cited by applicant]
Lu et al., “Innate Immune Regulations and Liver Ischemia-Reperfusion Injury.” Trasplantation, vol. 100, pp. 2601-2610 (2016).
[cited by applicant]
Lundbäck et al., “A novel high mobility group box 1 neutralizing chimeric antibody attenuates drug-induced liver injury and postinjury inflammation in mice.” Hepatology vol. 64, pp. 1699-1710 (2016).
[cited by applicant]
Ly et al., “The proteoglycan bikunin has a defined sequence.” Nat. Chem. Biol., vol. 7, pp. 827-833 (2011).
[cited by applicant]
Macchione et al., “Synthesis of chondroitin sulfate oligosaccharides using N-tetrachlorophthaloyl and N-trifluoroacetyl galactosamine building blocks,” European Journal of Organic Chemistry, pp. 3868-3884 (2014).
[cited by applicant]
Mackman, “Triggers, targets and treatments for thrombosis,” Nature, vol. 451, No. 21, pp. 914-918 (Feb. 21, 2008).
[cited by applicant]
Mahe, I.; Chidac, J.; Helfer, H.; Nobel, S. J. Thromb. Haemost. 2016, 14, 2017 . . . .
[cited by applicant]
Man et al., “Tolerance of the liver to intermittent pringle maneuver in hepatectomy for liver tumors.” JAMA Sirgery, vol. 134, pp. 533-539 (1999).
[cited by applicant]
Marcum, J. A. et al., “The origin of the dispute over the discovery of heparin,” J. Hist. Med. Allled Sci., vol. 55, pp. No. 1, 37-66, Jan. 1, 2000.
[cited by applicant]
Martinez-Gonzalez et al., “New Challenges for a Second-Generation Low-Molecular-Weight Heparin: Focus on Bemiparin,” Expert Rev. Cardiovasc. Ther., vol. 8, No. 5, pp. 625-634 (2010).
[cited by applicant]
Maza, S., et al., “Synthesis of chondroitin/dermatan sulfate-like oligosaccharides and evaluation of their protein affinity by fluorescence polarization.” Org. Biomol. Chem., vol. 11, pp. 3510-3525 (2013).
[cited by applicant]
Mazany et al., “Human chondroitin 6-sulfotransferase: cloning, gene structure, and chromosomal localization,” Biochimica et Biophysica Acta, vol. 1407, pp. 92-97 (1998).
[cited by applicant]
McGowan, K. E.; Makari, J.; Diamantouros, A.; Bucci, C.; Rempel, P.; Selby, R.; Geerts, W. Blood 2016, 127, 1954.
[cited by applicant]
Miyachi et al., “Syntheses of chondroitin sulfate tetrasaccharide structures containing 4,6-disulfate patterns and analysis of their interaction with glycosaminoglycan-binding protein.” Bioorg. Med. Chem. Lett., vol. 25…
[cited by applicant]
Miyata et al., “Persistent cortical plasticity by upregulation of chondroitin 6-sulfation.” Nat. Neurosci., vol. 15, pp. 414-422 (2012).
[cited by applicant]
Mizumoto et al., “Molecular interactions between chondroitin-dermatan sulfate and growth factors/receptors/matrix proteins.” Curr. Opin. Struct. Biol., vol. 34, pp. 35-42 (2015).
[cited by applicant]
Monneau et al., “The sweet spot: how GAGs help chemokines guide migrating cells.” J. Leukoc. Biol. vol. 99, pp. 935-953 (2016).
[cited by applicant]
Moon et al., “Dissecting the substrate recognition of 3-O-suflotransferase for the biosynthesis of anticoagulant heparin,” Proceedings of the National Academy of Sciences, vol. 109, No. 14, pp. 5265-5270 (2012).
[cited by applicant]
Mossanen et al., “Acetaminophen-induced acute liver injury in mice.” Lab. Anim. vol. 49, pp. 30-36 (2015).
[cited by applicant]
Mousa, “Drug Discovery and Evaluation: Pharmacological Assays” (ed. Vogel, H.), 393-456 (Springer-Verlag Berlin, Heidelberg, New York (2008).
[cited by applicant]
Mousa, “Heparin and Low-Molecular Weight Heparins in Thrombosis and Beyond,” Meth. Mol. Biol., vol. 663, pp. 109-132 (2010).
[cited by applicant]
Mousa, “In Vitro Methods of Evaluating Antithrombotics and Thrombolytics,” Meth. Mol. Biol., vol. 663, pp. 1-28 (2010).
[cited by applicant]
Munoz E., et al., “Affinity, kinetic, and structural study of the interaction of 3-O-sulfotransferase isoform 1 with Heparan Sulfate”, Biochemistry, vol. 45, No. 16, 2006, pp. 5122-5128.
[cited by applicant]
Munoz et al., “Enzymatic synthesis of heparin related polysaccharides on sensor chips: Rapid screening of heparin-protein interactions.” Biochemical and Biophysical Research Communications, Academic Press Inc., Orlando,…
[cited by applicant]
Nadanaka et al., “Characteristic Hexasaccharide Sequences in Octasaccharides Derived from Shark Cartilage Chondroitin Sulfate D with a Neurite Outgrowth Promoting Activity,” The Journal of Biological Chemistry, vol. 273…
[cited by applicant]
Nagano et al., “Chondroitin sulfate protects vascular endothelial cells from toxicities of extracellular histones.” Eur. J. Pharmacol., vol. 826, pp. 48-55 (2018).
[cited by applicant]
Nam et al., “Syndecan-1 Limits the Progression of Liver Injury and Promotes Liver Repair in Acetaminophen-Induced Liver Injury in Mice.” Hepatology, vol. 66(5), pp. 1601-1615, doi: 10.1002/hep.29265 (2017).
[cited by applicant]
Nastuk et al., “Expression Cloning and Characterization of NSIST, a Novel Sulfotransferase Expressed by a Subset of Neurons and Postsynaptic Targets,” The Journal of Neuroscience, vol. 18, No. 18, pp. 7167-7177 (Sep. 15…
[cited by applicant]
Noti et al., “Chemical Approaches to Define the Review Structure-Activity Relationship of Heparin-like Glycosaminoglycans,” Chemistry & Biology, vol. 12, pp. 731-756 (Jul. 2005).
[cited by applicant]
Notice of Allowance and Interview Summary corresponding to U.S. Appl. No. 14/898,865 dated Dec. 15, 2017.
[cited by applicant]
Notice of Allowance and Interview Summary corresponding to U.S. Appl. No. 17/254,145 dated Jan. 30, 2023.
[cited by applicant]
Notice of Allowance corresponding to U.S. Appl. No. 17/254,145 dated Dec. 8, 2022.
[cited by applicant]
Notice of Allowance corresponding to U.S. Appl. No. 16/492,858 dated Sep. 12, 2022.
[cited by applicant]
Notice of Allowance corresponding to U.S. Appl. No. 16/492,858 dated Feb. 10, 2023.
[cited by applicant]
Notice of Allowance corresponding to U.S. Appl. No. 13/996,930 dated Aug. 11, 2021.
[cited by applicant]
Notice of Allowance corresponding to U.S. Appl. No. 16/761,159 dated Aug. 24, 2023.
[cited by applicant]
Notice of Allowance corresponding to U.S. Appl. No. 16/761,159 dated Dec. 4, 2023.
[cited by applicant]
Notice of Allowance corresponding to U.S. Appl. No. 16/492,858 dated May 24, 2023.
[cited by applicant]
Notice of Allowance corresponding to U.S. Appl. No. 16/492,858 dated Sep. 7, 2023.
[cited by applicant]
Notice of Allowance corresponding to U.S. Appl. No. 16/492,858 dated Dec. 21, 2023.
[cited by applicant]
Notice of Publication Corresponding to European Patent Application. No. 19822610.2 dated Mar. 31. 2021.
[cited by applicant]
Notice of Publication Corresponding to European Patent application No. 18764628.6 dated Nov. 20, 2019.
[cited by applicant]
Notice of Publication Corresponding to European Patent Application No. 18873131.9 dated Jul. 15, 2020.
[cited by applicant]
Oduah et al., “Heparin: Past, present, and future.” Pharmaceuticals (Basel), vol. 9, Article No. 38 (2016).
[cited by applicant]
Office Action (Annex to the communication) corresponding to European Patent Application No. 18873131.9 dated Apr. 4, 2024, 7 Pages.
[cited by applicant]
Office Action (Decision to grant) corresponding to European Patent Application No. 18873131.9 dated Feb. 13, 2025, 3 Pages.
[cited by applicant]
Office Action (Decision of Rejection) corresponding to Chinese Patent Application No. 20180020095.X dated Dec. 1, 2022, pp. 10 (Translation).
[cited by applicant]
Office Action (Decision to grant) corresponding to European Patent Application No. 11849994.6 dated Jan. 13, 2022.
[cited by applicant]
Office Action (European Search Report) corresponding to European Patent Application No. 11849994.6 dated Apr. 1, 2016.
[cited by applicant]
Office Action (Final Rejection) corresponding to U.S. Appl. No. 13/996,930 dated Jun. 22, 2020.
[cited by applicant]
Office Action (Final) corresponding to U.S. Appl. No. 13/417,641 dated Sep. 5, 2013.
[cited by applicant]
Office Action (Final) corresponding to U.S. Appl. No. 16/625,342 dated Nov. 4, 2022.
[cited by applicant]
Office Action (Non- Final Rejection) corresponding to U.S. Appl. No. 18/138,596 dated Jun. 5, 2024.
[cited by applicant]
Office Action (non-final) corresponding to U.S. Appl. No. 13/417,641 dated Feb. 11, 2013.
[cited by applicant]
Office Action (Notice of Allowance) corresponding to U.S. Appl. No. 13/417,641 dated Feb. 27, 2014.
[cited by applicant]
Office Action (Notice of Allowance) corresponding to U.S. Appl. No. 13/996,930 dated Nov. 24, 2021.
[cited by applicant]
Office Action (Notice of Allowance) corresponding to U.S. Appl. No. 16/625,342 dated Jan. 10, 2024.
[cited by applicant]
Office Action (Notice of Allowance) corresponding to U.S. Appl. No. 16/625,342 dated Jan. 19, 2024.
[cited by applicant]
Office Action (Notice of Allowance) corresponding to U.S. Appl. No. 16/625,342 dated Apr. 26, 2024.
[cited by applicant]
Office Action (Notice of Reasons for Rejection) corresponding to Japanese Patent Application No. 2020-570916 dated Jun. 20, 2023.
[cited by applicant]
Office Action (Notice of Reasons for Rejection) corresponding to Japanese Patent Application No. 2020-570916 dated Jan. 16, 2024.
[cited by applicant]
Office Action (Notice of Reasons for Rejection) corresponding to Japanese Patent Application No. 2023-129964 dated Oct. 8, 2024, 14 pages.
[cited by applicant]
Office Action (Notice of Reasons for Rejection) corresponding to Japanese Patent Application No. 2022-527682 dated Oct. 29, 2024, pp. 8.
[cited by applicant]
Office Action (Restriction Requirement) corresponding to U.S. Appl. No. 16/625,342 dated Dec. 16, 2021.
[cited by applicant]
Office Action (Restriction Requirement) corresponding to U.S. Appl. No. 17/254,145 dated Nov. 26, 2021.
[cited by applicant]
Office Action (Restriction Requirement) corresponding to U.S. Appl. No. 16/761,159 dated Jun. 10, 2022.
[cited by applicant]
Office Action (Restriction Requirement) corresponding to U.S. Appl. No. 16/492,858 dated Jun. 30, 2021.
[cited by applicant]
Office Action (Restriction Requirement) corresponding to U.S. Appl. No. 11/920,319 dated Jan. 27.2010.
[cited by applicant]
Office Action (Restriction Requirement) corresponding to U.S. Appl. No. 13/417,641 dated Dec. 27, 2012.
[cited by applicant]
Office Action (Restriction Requirement) corresponding to U.S. Appl. No. 13/996,930 dated Mar. 17, 2015.
[cited by applicant]
Office Action (Restriction Requirement) corresponding to U.S. Appl. No. 17/744,407 dated Nov. 15, 2024.
[cited by applicant]
Non-Final Office Action corresponding to U.S. Appl. No. 17/744,407 dated Feb. 26, 2025.
[cited by applicant]
Office Action (Restriction Requirement) corresponding to U.S. Appl. No. 18/222,910 dated Dec. 6, 2024, 9 Pages.
[cited by applicant]
Office Action (Restriction Requirement) corresponding to U.S. Appl. No. 18/222,910 dated Feb. 26, 2025, 11 Pages.
[cited by applicant]
Office Action corresponding to Chinese Application No. 202080092829.2 dated Jun. 21, 2023.
[cited by applicant]
Office Action (Decision of Rejection) corresponding to Chinese Application No. 202080092829.2 dated Mar. 3, 2024, pp. 19.
[cited by applicant]
Office Action corresponding to Chinese Patent Application No. 201880020095.X dated Jun. 8, 2022.
[cited by applicant]
Office Action corresponding to Chinese Patent Application No. 201480044429.9 dated Aug. 30, 2018, pp. 43.
[cited by applicant]
Office Action corresponding to Chinese Patent Application No. 201480044429.9 dated Apr. 9, 2019.
[cited by applicant]
Office Action corresponding to Chinese Patent Application No. 201480044429.9 dated Mar. 3, 2020.
[cited by applicant]
Office Action corresponding to Chinese Patent Application No. 201880020095.X dated Sep. 22, 2021.
[cited by applicant]
Office Action corresponding to Chinese Patent Application No. 2018800850125 dated Jan. 20, 2023.
[cited by applicant]
Office Action corresponding to Chinese Patent Application No. 201880020095.X dated Apr. 18, 2023.
[cited by applicant]
Office Action corresponding to Chinese Patent Application No. 201980044697.3 dated Jul. 7, 2023.
[cited by applicant]
Office Action corresponding to Chinese Patent Application No. 201880085012.5 dated Nov. 30, 2023.
[cited by applicant]
Office Action corresponding to Chinese patent Application No. 202310342719.2 dated May 8, 2023.
[cited by applicant]
Office Action corresponding to Chinese Patent Application No. 202080092 dated Jun. 21, 2023.
[cited by applicant]
Office Action corresponding to Chinese patent Application No. 202310342719.2 dated Feb. 28, 2024.
[cited by applicant]
Office Action corresponding to Chinese patent Application No. 202310342719.2 dated Jul. 24, 2024, 8 Pages.
[cited by applicant]
Office Action corresponding to Chinese patent Application No. 202310342719.2 dated Oct. 16, 2024, pp. 11.
[cited by applicant]
Office Action corresponding to European Patent Application No. 11849994.6 dated May 24, 2018.
[cited by applicant]
Office Action corresponding to European Patent Application No. 11849994.6 dated Jan. 22, 2020.
[cited by applicant]
Office Action corresponding to European Patent Application No. 14812890.3 dated Jun. 23, 2020.
[cited by applicant]
Office Action corresponding to European Patent Application No. 18873131.9-1112 dated Aug. 14, 2023.
[cited by applicant]
Office Action corresponding to European Patent Application No. 18764628.6 dated Nov. 16, 2023.
[cited by applicant]
Office Action corresponding to Japanese Patent Application No. 2019-549419 dated Dec. 23, 2022, pp. 3.
[cited by applicant]
Office Action corresponding to Japanese Patent Application No. 2016-521505 dated Jul. 19, 2018.
[cited by applicant]
Office Action corresponding to Japanese Patent Application No. 2016-521505 dated Jun. 21, 2019.
[cited by applicant]
Office Action corresponding to Japanese Patent Application No. 2019-549419 dated Mar. 22, 2022.
[cited by applicant]
Office Action corresponding to Japanese Patent Application No. 2020-544568 dated Jan. 10, 2023.
[cited by applicant]
Office Action corresponding to Japanese Patent Application No. 2024-008526 dated Dec. 24, 2024, pp. 4—English summary provided.
[cited by applicant]
Office Action Corresponding to Japanese Patent Application Serial No. 2020-544568 dated Sep. 26, 2023.
[cited by applicant]
Office Action corresponding to U.S. Appl. No. 12/178,434 dated Oct. 28, 2011.
[cited by applicant]
Office Action corresponding to U.S. Appl. No. 12/178,434 dated Apr. 19, 2011.
[cited by applicant]
Office Action corresponding to U.S. Appl. No. 12/178,434 dated Jan. 26, 2011.
[cited by applicant]
Office Action corresponding to U.S. Appl. No. 16/492,858 dated Jan. 13, 2022.
[cited by applicant]
Office Action corresponding to U.S. Appl. No. 16/625,342 dated Mar. 21, 2022.
[cited by applicant]
Office Action corresponding to U.S. Appl. No. 16/761,159 dated Jan. 11, 2023.
[cited by applicant]
Office Action corresponding to U.S. Appl. No. 17/254,145 dated Feb. 16, 2022.
[cited by applicant]
Office Action corresponding to U.S. Appl. No. 13/996,930 dated Oct. 8, 2015.
[cited by applicant]
Office Action corresponding to U.S. Appl. No. 13/996,930 dated May 26, 2016.
[cited by applicant]
Office Action corresponding to U.S. Appl. No. 13/996,930 dated Dec. 21, 2017.
[cited by applicant]